Lunit noted that six studies featuring the use of its AI technology will be presented at the Society for Immunotherapy of Cancer (SITC) 2023 meeting being held November 1 to 5 in San Diego.
The studies highlight the predictive value and analytical power of the company’s Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer, Lunit said.
Lunit’s SCOPE IO software analyzes a patient’s cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes, which fight cancer cells. Based on the spatial distribution pattern of tumor-infiltrating lymphocytes, the software may help clinicians identify patients at higher risk, the company said.
